Corporate
2016.06.02
LT1001 out-licensed to China
Lumosa Therapeutics Co., Ltd. announced today the signing of an exclusive license agreement with Syntano Technology Venture - a Haike company (Syntano), granting Syntano the right to develop and commercialize its LT1001 product in China, Hong Kong and Macau.commercial successes with this product by our partners. Lumosa will continue to develop high potential new drugs, maximize the value of our pipeline assets and bring our shareholders the most returns”, said Dr. Tsai Chang-Hai, Chairman of Lumosa Company Board. Please click link for more information
LT1001 is a long-acting analgesic injection administered intramuscularly in a proprietary sustained- release formulation of sebacoyl dinalbuphine ester (SDE), a prodrug of nalbuphine. Clinical trial
showed LT1001 is safe and effective in relieving post-hemorrhoidectomy pain for up to seven days, while most of the commercially available analgesic medications relief pain for only 2 to 6 hours. Lumosa filed a New Drug Application (NDA) for LT1001 with Taiwan Food and Drug Administration last September and signed an exclusive license agreement with InteRx BioMedical Co., Ltd. for the commercialization of LT1001 in Taiwan last December.
Under this agreement, Syntano will be responsible for all development activities required to obtainmarket authorizations in China, Hong Kong and Macau, as well as the subsequent commercialization activities. Lumosa will receive upfront and milestone payments from Syntano upon achieving specified development and registration related milestones. In addition, Lumosa will receive royalties linked to product sales of LT1001 in China, Hong Kong and Macau. “As recognized by our partners in Taiwan and China, LT1001 is a highly differentiated product, which not only addresses unmet medical needs in pain management, but holds a great marketability and commercial potential. I look forward to seeing great commercial successes with this product by our partners. Lumosa will continue to develop high potential new drugs, maximize the value of our pipeline assets and bring our shareholders the most returns”, said Dr. Tsai Chang-Hai, Chairman of Lumosa Company Board.
About Lumosa: Lumosa Therapeutics is dedicated to the development of innovative new drugs for unmet medical needs in the fields of CNS and inflammatory diseases. The company is actively engaged in scientific licensing and new drug development under a “reSEARCH and DEVELOPMENT” model. We “search” for candidates with strong scientific rationale and high feasibility of technical success, and progress them to novel therapies via inventive and effective development programs. We seek international partners for collaboration in clinical trial and/or product development to advance pipeline assets. Currently our two front runners are LT1001 for moderate to severe pain relief and LT3001 for acute ischemic stroke.
About Syntano: Syntano is a wholly owned subsidiary of Haike Group (http://haikegroup.com), which was founded in1988 and became the first petrochemical company to be listed in London Stock Exchange in 2007. Today Haike Group is a conglomerate of petrochemical, biopharmaceutical, and international finance and trade companies with a total annual revenue of 43.4 billion Yuan, ranking 293th among the top 500 Chinese enterprises. Haike is actively seeking innovative differentiated drug products to expand its biopharmaceutical business and has established Syntano as its dedicated division for the development and marketing of special chemicals and new drug products. Since company’s inception Syntano has recruited and built a highly experienced professional team for long-term investment in drug development projects; focusing on pain management, central nervous system diseases, autoimmune diseases, and oncology.
LT1001 is a long-acting analgesic injection administered intramuscularly in a proprietary sustained- release formulation of sebacoyl dinalbuphine ester (SDE), a prodrug of nalbuphine. Clinical trial
showed LT1001 is safe and effective in relieving post-hemorrhoidectomy pain for up to seven days, while most of the commercially available analgesic medications relief pain for only 2 to 6 hours. Lumosa filed a New Drug Application (NDA) for LT1001 with Taiwan Food and Drug Administration last September and signed an exclusive license agreement with InteRx BioMedical Co., Ltd. for the commercialization of LT1001 in Taiwan last December.
Under this agreement, Syntano will be responsible for all development activities required to obtainmarket authorizations in China, Hong Kong and Macau, as well as the subsequent commercialization activities. Lumosa will receive upfront and milestone payments from Syntano upon achieving specified development and registration related milestones. In addition, Lumosa will receive royalties linked to product sales of LT1001 in China, Hong Kong and Macau. “As recognized by our partners in Taiwan and China, LT1001 is a highly differentiated product, which not only addresses unmet medical needs in pain management, but holds a great marketability and commercial potential. I look forward to seeing great commercial successes with this product by our partners. Lumosa will continue to develop high potential new drugs, maximize the value of our pipeline assets and bring our shareholders the most returns”, said Dr. Tsai Chang-Hai, Chairman of Lumosa Company Board.
About Lumosa: Lumosa Therapeutics is dedicated to the development of innovative new drugs for unmet medical needs in the fields of CNS and inflammatory diseases. The company is actively engaged in scientific licensing and new drug development under a “reSEARCH and DEVELOPMENT” model. We “search” for candidates with strong scientific rationale and high feasibility of technical success, and progress them to novel therapies via inventive and effective development programs. We seek international partners for collaboration in clinical trial and/or product development to advance pipeline assets. Currently our two front runners are LT1001 for moderate to severe pain relief and LT3001 for acute ischemic stroke.
About Syntano: Syntano is a wholly owned subsidiary of Haike Group (http://haikegroup.com), which was founded in1988 and became the first petrochemical company to be listed in London Stock Exchange in 2007. Today Haike Group is a conglomerate of petrochemical, biopharmaceutical, and international finance and trade companies with a total annual revenue of 43.4 billion Yuan, ranking 293th among the top 500 Chinese enterprises. Haike is actively seeking innovative differentiated drug products to expand its biopharmaceutical business and has established Syntano as its dedicated division for the development and marketing of special chemicals and new drug products. Since company’s inception Syntano has recruited and built a highly experienced professional team for long-term investment in drug development projects; focusing on pain management, central nervous system diseases, autoimmune diseases, and oncology.
